↓ Skip to main content

Efficacy of trabectedin in malignant solitary fibrous tumors: a retrospective analysis from the French Sarcoma Group

Overview of attention for article published in BMC Cancer, October 2015
Altmetric Badge

Mentioned by

twitter
1 tweeter

Citations

dimensions_citation
20 Dimensions

Readers on

mendeley
11 Mendeley
Title
Efficacy of trabectedin in malignant solitary fibrous tumors: a retrospective analysis from the French Sarcoma Group
Published in
BMC Cancer, October 2015
DOI 10.1186/s12885-015-1697-8
Pubmed ID
Authors

J. Khalifa, M. Ouali, L. Chaltiel, S. Le Guellec, A. Le Cesne, J-Y Blay, P. Cousin, L. Chaigneau, E. Bompas, S. Piperno-Neumann, B. Bui-Nguyen, M. Rios, J-P Delord, N. Penel, C. Chevreau

Abstract

Advanced malignant solitary fibrous tumors (SFTs) are rare soft-tissue sarcomas with a poor prognosis. Several treatment options have been reported, but with uncertain rates of efficacy. Our aim is to describe the activity of trabectedin in a retrospective, multi-center French series of patients with SFTs. Patients were mainly identified through the French RetrospectYon database and were treated between January 2008 and May 2013. Trabectedin was administered at an initial dose of 1.5 mg/m(2), q3 weeks. The best tumor response was assessed according to the Response Evaluation Criteria In Solid Tumors 1.1. The Kaplan-Meier method was used to estimate median progression-free survival (PFS) and overall survival (OS). The growth-modulation index (GMI) was defined as the ratio between the time to progression with trabectedin (TTPn) and the TTP with the immediately prior line of treatment (TTPn-1). Eleven patients treated with trabectedin for advanced SFT were identified. Trabectedin had been used as second-line treatment in 8 patients (72.7 %) and as at least third-line therapy in a further 3 (27.3 %). The best RECIST response was a partial response (PR) in one patient (9.1 %) and stable disease (SD) in eight patients (72.7 %). Disease-control rate (DCR = PR + SD) was 81.8 %. After a median follow-up of 29.2 months, the median PFS was 11.6 months (95 % CI = 2.0; 15.2 months) and the median OS was 22.3 months (95 % CI = 9.1 months; not reached). The median GMI was 1.49 (range: 0.11-4.12). Trabectedin is a very promising treatment for advanced SFTs. Further investigations are needed.

Twitter Demographics

The data shown below were collected from the profile of 1 tweeter who shared this research output. Click here to find out more about how the information was compiled.

Mendeley readers

The data shown below were compiled from readership statistics for 11 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
Italy 1 9%
Unknown 10 91%

Demographic breakdown

Readers by professional status Count As %
Student > Ph. D. Student 3 27%
Student > Postgraduate 3 27%
Other 2 18%
Researcher 2 18%
Unspecified 1 9%
Other 0 0%
Readers by discipline Count As %
Medicine and Dentistry 7 64%
Unspecified 2 18%
Agricultural and Biological Sciences 1 9%
Pharmacology, Toxicology and Pharmaceutical Science 1 9%

Attention Score in Context

This research output has an Altmetric Attention Score of 1. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 15 October 2015.
All research outputs
#4,618,788
of 6,245,029 outputs
Outputs from BMC Cancer
#1,954
of 3,067 outputs
Outputs of similar age
#132,505
of 195,073 outputs
Outputs of similar age from BMC Cancer
#127
of 225 outputs
Altmetric has tracked 6,245,029 research outputs across all sources so far. This one is in the 15th percentile – i.e., 15% of other outputs scored the same or lower than it.
So far Altmetric has tracked 3,067 research outputs from this source. They receive a mean Attention Score of 2.9. This one is in the 21st percentile – i.e., 21% of its peers scored the same or lower than it.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 195,073 tracked outputs that were published within six weeks on either side of this one in any source. This one is in the 21st percentile – i.e., 21% of its contemporaries scored the same or lower than it.
We're also able to compare this research output to 225 others from the same source and published within six weeks on either side of this one. This one is in the 26th percentile – i.e., 26% of its contemporaries scored the same or lower than it.